Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Topline Results From Tofersen Phase 3 Study And Its Open Label Extension In Sod1 Als To Be Presented At The American Neurological Association Annual Meeting is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study
With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound. Read More
Blow to Biogen as ALS hope tofersen flunks phase 3 trial
Tofersen missed its primary objective in the VALOR study, with patients ... to meet its targets in a phase 2/3 trial earlier this year. Last year, Biogen expanded its ALS pipeline by forging ... Read More
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
PHOENIX Study Results: The Phase 3 PHOENIX ... with ALS encompassing a 6-month randomized, placebo-controlled phase and an open-label long-term follow-up phase. The trial met its primary efficacy ... Read More
Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive
(RTTNews) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) Monday said it presented positive topline results from the Phase 3 MELODY-1 study of its drug candidate PL9643 in dry eye disease ... Read More
LENZ Therapeutics announces positive topline results from Phase 3 CLARITY study
Results showed LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, while LNZ101 showed similar results but ultimately failed to show superiority to LNZ100. Read More
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
The Phase 2 study is a randomized, open-label ... press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, topline ... Read More
Biophytis presented its phase 3 protocol in the treatment of sarcopenia
The SARA-INT phase 2 study showed promising results ... and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information, visit ... Read More
Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive
Monday said it presented positive topline results from the Phase 3 MELODY-1 study of its drug candidate PL9643 in dry eye disease at the American Society of Cataract and Refractive Surgery (ASCRS). Read More
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
today announced positive topline results from its open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of ... Read More
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
today announced positive topline results from its open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus